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that a proportional decrease in list price decreased the ICER disproportionally in favor 
of adding a single dose of PCV13.
Conclusion. Expanding the recommendation of only PPV23 to PCV13→PPV23 
among Dutch adults aged 60  years and older is a cost-effective use of healthcare 
resources. In particular adding a single dose of PCV13 for those with moderate or high 
risk of pneumococcal disease was shown to be cost-saving.
Disclosures. M. Rozenbaum, Pfizer: Employee and Shareholder, Salary.
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Background. Despite the current vaccination program in Argentina for older 
adults (OA), influenza continues to have severe consequences. Estimates based on 
Argentinian information surveillance system suggest that influenza-like illness reaches 
an average rate of 3,570/100,000 annually, a hospitalization rate of 15.5/100,000 and a 
death rate of 0.32/100,000 in OA aged 65+. The high burden of disease in this popula-
tion is in part due to immunosenescence and the resulting suboptimal clinical effect-
iveness of influenza vaccines in this age group. There is an unmet clinical need in those 
aged 65+ for an influenza vaccine that offers enhanced protection. The objective of 
this study was to evaluate the cost effectiveness (CE) of the MF59 adjuvanted vaccine 
(aTIV) in Argentina compared with current vaccination policy with an un-adjuvanted 
vaccine (TIV).
Methods. A static decision tree CE model of aTIV was developed to estimate the 
cost effectiveness compared with TIV vaccine in those aged 65+ in Argentina. The 
model compares cost and health benefits of vaccination in an influenza season from 
the payer and the societal perspective. The main outcomes include events, death, LLY, 
QALYs, and costs. To the extent possible, model inputs were sourced from Argentina; 
in cases where local data were insufficient, international inputs were utilized. Vaccine 
efficacy assumptions were extracted from recent literature search.
Results. Using aTIV instead of TIV resulted in additional 530 deaths averted 
and 3,980 incremental quality-adjusted life-years (QALYs) gained. The incremental 
cost-effectiveness ratio (ICER) was US$243 and US$937 per QALY from societal and 
payer´s perspective respectively. In all univariate sensitivity analyses, aTIV remained 
highly cost-effective meeting the threshold of one GDP per capita in Argentina. From 
a societal perspective, the probabilistic sensitivity analyses showed aTIV cost-saving in 
30% of the simulations.
Conclusion. This analysis suggests that vaccinating with aTIV in Argentina 
would be a highly cost-effective in providing additional health gains while reducing 
healthcare resources utilization and costs.
Disclosures. N. Giglio, Sanofi Pasteur: Consultant, Speaker honorarium.
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Background. In 2014, pneumococcal conjugate (PCV13) and polysaccharide 
(PPSV23) vaccines were recommended in series for all US adults ≥65 years. We con-
ducted a case–control study to evaluate risk factors for invasive pneumococcal disease 
(IPD) among adults ≥65 years old.
Methods. IPD cases (isolation of pneumococcus from sterile sites) were identified 
through Active Bacterial Core surveillance during 2015–2018. Isolates were serotyped 
using whole genome sequencing. Four controls, identified through a commercial data-
base, were matched per case by age and zip code. We obtained vaccination and medical 
histories from providers, vaccine registries and participant interviews. A  functional 
status score was calculated based on participant interview. We calculated IPD odds 
ratios using multivariable conditional logistic regression.
Results. We enrolled 328 IPD cases and 1,280 matched controls. Fifty percent 
of case-patients and 55% of controls received a dose of PCV13. Case-patients were 
more likely than controls to have a chronic condition (heart, liver, or lung disease, dia-
betes, cochlear implant, alcohol abuse, smoking; 82% vs. 59%), immunosuppression 
(60% vs. 32%), poor functional status (score of ≥ 3; 71% vs. 50%), annual household 
income <$30,000 (38% vs. 25%) and education level of high school or less (36% vs. 
25%). In a multivariable model, case-patients were more likely than controls to have a 
chronic condition (OR 2.48, 95% CI 1.72, 3.58), immunosuppression (OR 2.56, 95% CI 
1.92,3.42), poor functional status (OR 3.66, 95% CI 2.42, 5.54), and primary or second-
ary smoking exposure (OR 3.09, 95% CI 1.32, 7.2). In analysis limited to PCV13-type 
cases and matched controls, adjusting for PCV13 receipt, measures of association were 
no longer significant for chronic conditions (OR 1.45, 95% 0.71, 2.95), immunosup-
pression (OR 1.51, 95% CI 0.83, 2.74), or poor functional status (OR 1.98, 95% CI 
0.91, 4.3).
Conclusion. Chronic and immunosuppressive conditions remain IPD risk fac-
tors for adults in the era of PCV13 use; poor functional status was also identified as a 
risk factor. Targeted evaluation of adults with poor functional status could inform IPD 
prevention strategies. PCV13 may reduce the risk of PCV13-type IPD associated with 
chronic conditions and poor functional status.
Disclosures. W. Schaffner, Merck: Member, Data Safety Monitoring Board, 
Consulting fee; Pfizer: Member, Data Safety Monitoring Board, Consulting fee
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Background. Minority adult populations are at a higher risk for invasive pneu-
mococcal disease and also have significantly lower vaccination rates when compared 
with the general population. Ingrained attitudes are a significant barrier to receipt of 
pneumococcal vaccine in these disparate populations, and therefore we tested targeted 
informational messaging to overcome these.
Methods. A survey instrument of attitudinal questions related to pneumococcal 
vaccination was administered via YouGov, an online public national survey house in 
2017. Socioeconomic information was captured and linked to baseline Likert scale atti-
tudinal question responses. Respondents were randomly assigned into subsamples that 
received different science-based messages that included information on pneumococcal 
vaccines related to: pneumonia prevention, fatality/consequences, vaccine safety infor-
mation, family duty/safety, and a combined vignette including all of these. Because of 
the random assignment, any differences observed in the respondents’ outcomes across 
subsamples can be attributed to the messages. Descriptive statistics were used to com-
pare the persuasive effectiveness of these messages to conventional vaccine informa-
tion across racial and ethnic groups.
Results. A total of 2,608 respondents, 1,327 (51%) white and 1,281 (49%) non-
white (over-sampled) were represented. Of the total respondents as well as in white, 
and non-white respondents, the combined vignette was associated with positive coef-
ficients of b = 0.26, b = 0.24, and b = 0.32, respectively (P-values all <0.05). In whites, 
the vaccine safety information and family duty/safety also had significant coefficients 
b = 0.24 ( = P = 0.012) and b = 0.24 (P = 0016), respectively. In non-Whites, fam-
ily duty/safety was the only additional message with a significant coefficient b = 0.25 
(P = 0.007).
Conclusion. In this survey assessing attitudes toward pneumococcal vaccination 
across racial and ethnic subpopulations, the disparate population was persuaded to 
receive the vaccine only when family duty and safety were linked within the informa-
tional messages. Future studies implementing this informational messaging strategy 
should be performed to validate this finding.
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Background. Coverage estimates for pneumococcal vaccination in the United 
States come from the National Health Interview Survey (NHIS) and do not differenti-
ate between 13-valent conjugated vaccine (PCV13) and 23-valent polysaccharide vac-
cine (PPSV23). This study was conducted to assess coverage of PCV13 among adults 
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